FERD3L (Fer3 like bHLH transcription factor) is a basic helix-loop-helix transcription factor that functions as a transcriptional inhibitor by binding E-box sequences and sequestering E proteins, thereby antagonizing transcription activation by ASCL1/MASH1. FERD3L operates through protein-DNA interactions requiring dimerization with E proteins and localizes to the nucleus where it regulates RNA polymerase II-dependent transcription. At the mechanistic level, FERD3L expression is epigenetically regulated; KDM5D, a histone H3K4 demethylase, directly represses FERD3L transcription through promoter occupancy and reduction of H3K4me3 marks 1. FERD3L methylation patterns show clinical significance, with differential methylation observed in triple-negative breast cancer, where elevated FERD3L methylation in responder patients contributes to a two-gene epigenetic signature (FERD3L and TRIP10) predicting pathological complete response to neoadjuvant chemotherapy with 78.6% accuracy 2. Disease relevance spans multiple conditions: FERD3L expression correlates with cardiovascular stability, with lower expression associated with unstable carotid plaques and increased ischemic stroke risk 34. In male colorectal cancer, FERD3L upregulation associates with advanced disease, lymph node metastasis, and poor prognosis, with KDM5D-mediated repression of FERD3L suppressing tumor cell proliferation, migration, and invasion while promoting apoptosis 1. Genetic variants near FERD3L (rs10230207) confer increased intracranial aneurysm risk, though FERD3L expression itself remains unaffected by this variant 5. FERD3L also associates with bone metabolism processes in osteoporosis 6.